Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

[p<0.0001].

-- Significantly greater mean increase in CD4+ cell count from baseline;

mean increase of 81 vs. 64 cells/mm(3)[p=0.0022]

The results of DUET-1 and DUET-2 were published separately in two articles in the July 7, 2007 issue of The Lancet, and the pooled analysis from the DUET studies was presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2007.

DUET-1 and -2 Resistance

-- The presence of K103N, which was the most prevalent NNRTI substitution

in DUET-1 and -2 studies at baseline, did not affect the response in

the INTELENCE arm.

-- The presence at baseline of the substitutions V179D, V179F, V179T,

Y181V, or G190S was associated with a decreased virologic response to

INTELENCE.

-- In the DUET-1 and -2 studies, the presence at baseline of three or more

2007 IAS-USA-defined NNRTI substitutions (V90I, A98G, L100I, K101E/P,

K103N, V106A/I/M, V108I, V179D/F, Y181C/I/V, Y188C/H/L, G190A/S, P225H)

resulted in a decreased virologic response to INTELENCE.

-- For patients in the DUET-1 and -2 studies experiencing virologic

failure on an INTELENCE-containing regimen, the substitutions that

occurred most commonly were V179F, V179I, Y181C, and Y181I which

usually emerged in a background of multiple other NNRTI

resistance-associated substitutions. Other NNRTI resistance-associated

substitutions which emerged in patients on INTELENCE treatment in

< 10 percent of the virologic failure isolates included K101E, K103N,

V106I/M, V108I, Y188L, V189I, G190S/C and R356K.

-- Cross-resistance to delavirdine, efavirenz, and/or nevirapine is

expected after virologic failure with an INTELENCE-containing regimen.

DUET-1 and -2 Tolerability

In the DUET-1 and -2 studies, the most common adverse events (> 10 percent) o
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Although RNA-Sequencing is ... first transcriptome-wide analyses appearing around 2008, RNA-Sequencing has ... RNA measurement. In the last several years, assays ... work with smaller input amounts, process degraded RNA, ... samples). On the bioinformatics side, there have been ...
(Date:7/31/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues, today announced ... will be released on Thursday, August 7, 2014, and ... live webcast at 4:30 p.m. ET that afternoon. Management ...
(Date:7/31/2014)... July 31, 2014 The Kidney Cancer Association ... its monthly news magazine, Kidney Cancer News. , Bill ... on a website maintained by an international news organization. When ... increase in viewers.” , This month’s program highlights news of ... analyzed in a recent study. Kidney Cancer News also ...
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... Thursday, November 5, 2009 at 4:30 p.m. Eastern Time ... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... third quarter and nine months ended September 30, 2009 ... of 2009. , The following consolidated results reflect the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... financial results for the third quarter ended September 30, ... September of this year, the FDA,s Arthritis Advisory Committee ... of XIAFLEX(TM) for the treatment of Dupuytren,s disease, and ...
... Texas, Nov. 5 Wound Management Technologies, Inc., (WNDM), announced ... to purchase all healthcare-related assets of Virtual Health Technologies, Inc. ... be paid $1,000,000 in cash and debt, 4,000,000 shares of ... on the Veriscrip technology being acquired from VHGI. ...
Cached Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
(Date:7/31/2014)... genes to the earliest common ancestor of butterflies ... an extensive "Tree of Lepidoptera" in the first ... , Among the study,s more surprising findings: Butterflies ... to large ones, which completely changes scientists, understanding ... that some insects once classified as moths are ...
(Date:7/31/2014)... It has long been known that biomass burning ... savannah as a ritual , slash-and-burn agriculture and ... public health. , But until the release of ... Environmental Engineering Professor Mark Z. Jacobson, the degree ... , Jacobson,s research, detailed in a paper published ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... A tale of two sisters has helped researchers solve ... causes an inherited form of the lung disease Pulmonary Alveolar ... Journal of Experimental Medicine , a research team led ... possibility of an inhaled therapy to overcome a chain of ...
... at the Johns Hopkins Bloomberg School of Public ... for potential human exposure to antibiotic-resistant bacteria from ... chickens from farm to slaughterhouse. A study by ... bacteria, both susceptible and drug-resistant, on surfaces and ...
... exercise seems to reduce anger expression in overweight but ... study on the topic looked at 208 typically sedentary ... afterschool aerobic exercise program or maintained their usual inactive ... common anger expressions such as slamming doors and hitting, ...
Cached Biology News:Inherited genetic cause, possible treatment found for complex lung disorder 2Inherited genetic cause, possible treatment found for complex lung disorder 3Transporting broiler chickens could spread antibiotic-resistant organisms 2Exercise helps overweight children reduce anger expression 2
...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used ... the data obtained from the Experion ... data in electropherogram and simulated gel ... other calculations in a Results table. ...
Biology Products: